Rhythm PharmaceuticalsRYTM
Recorded

Rhythm Pharmaceuticals 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration26 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Seamus FernandezSenior Managing Director

Is this on? Great. Well, good morning, everyone, and thanks for joining us today, here for another of Guggenheim's annual conferences, our Healthcare Innovation Conference 2026. To my left is the CEO, president, and Chairman of Rhythm Pharmaceuticals, David Meeker. David's going to kick us off with a few opening remarks, and then we'll jump right into Q&A.

David MeekerChairman, President, and CEO

David. Yeah. Thanks, Seamus, and thanks for having us.

David MeekerChairman, President, and CEO

Just one comment. Obviously, we're aware of the media reports, and we don't comment on media reports or any of the rumors out there, and so we won't be having anything else to say about that today, but really look forward to talking about the business.

Seamus FernandezSenior Managing Director

Great. Just as a starting point, you've described the strategic pillars for MC4R agonism development, genetic hypothalamic obesity, Prader-Willi. Maybe you can just kind of talk about the opportunities that you see kind of going forward, and just the size of the market opportunity that you see ahead.

David MeekerChairman, President, and CEO

Yeah. I think one of the most interesting things about Rhythm has been that this is very old biology. I mean, companies, or academia and industry have been working on this for decades, the MC4R pathway. That pathway, which governs satiety and energy expenditure, was well understood. Obviously, if you have impaired signaling, then it leads to obesity. But in many cases, a very significant part of the pathology and what leads to the patient discomfort is this hunger, which is, it's not just, "I feel hungry because I missed lunch," but it's just a completely abnormal preoccupation with food and need to seek food and the like. But that part of the biology has been very well understood. I think what was not so well understood, that early understanding came from the genetic causes, and so that's where Rhythm pursued our initial indications.

David MeekerChairman, President, and CEO

And in fact, some of those results were quite profound and gave us a lot of confidence in the biology. But what's been really interesting over the past five or six years is a growing understanding of other diseases where it wasn't so obvious that this pathway was central to those diseases, and HO is a prime example. I famously say when I started in this role back in 2020, the company had just started the HO trial, and I thought the probability that trial would be successful was very low because you could imagine that if you injure the hypothalamus, you might lose this pathway, but the idea that you're probably losing receptors as well, and so, how does an agonist work in that setting? So, the consistent, and that's been the most striking thing.

David MeekerChairman, President, and CEO

I mean, we had quite profound results, but the consistency of those profound results was really remarkable. Now we're into Prader-Willi, an incredibly complex disease, many genes eliminated, but again, a growing confidence that this MC4R pathway is central to a number of the things that those patients are suffering with. So yeah, we're excited about the potential growth opportunities.

Seamus FernandezSenior Managing Director

Last week, you announced the amendment to the LG Chem agreement, and as an older analyst in the space, I kind of go back to the bold move that Cephalon actually made way back when they bought back a substantial percentage of their royalty. To me, this feels very similar in a lot of ways. Can you just talk about the structure of that agreement and what you saw as the sort of benefits of doing this now in particular?

David MeekerChairman, President, and CEO

Sure. Yeah, I mean, that partnership deal with LG Chem, I mean, they've really been incredibly wonderful, constructive partners in this. When we did the deal originally, it was early on in our understanding of the HO opportunity. I think over the past year, and certainly since approval in the U.S., our confidence in that opportunity has continued to grow significantly. So, what this buy-down in the royalty really reflects is a lot of confidence in the future there. I think if we perform as expected, then the economics around this deal can be supported only on the basis of HO. The other part of that deal, which, as I said in my comments, despite our best efforts to align the two companies, and that was done by not having a royalty only on bivamelagon.

David MeekerChairman, President, and CEO

LG Chem might have been, and they were, concerned that if we were separated in that way, there might be a disincentive for Rhythm to promote their product, that bivamelagon, over a Rhythm fully owned product, and that was understandable. The royalties always applied across the whole portfolio, and that was what allowed all of us to get comfortable. There was one wrinkle to that, which was, for each new indication that we developed with bivamelagon, the royalty rate went up by a point, and it would max out at 7%. As we got more confidence in bivamelagon and found that that molecule as a backbone, either as a monotherapy or potentially a combination therapy, we didn't want that disincentive. It didn't make sense. I think it wasn't in the best interest of both parties. This really did both of those things.

David MeekerChairman, President, and CEO

It speaks to our confidence in the future, number one, but it also cleans up the agreement. So now, any decisions we make around our portfolio will be driven solely by science, what we think is the best applicable molecule for a potential indication and the like. We've said, and I think this is likely, that for the big opportunities, HO and Prader-Willi in this case, we're likely to develop both the daily oral and RM-718 weekly formulation, because those are big opportunities. We want patients to have the option for two. For some of the smaller ones, it won't make sense to develop both, and you can imagine we pick one or the other to go forward.

Seamus FernandezSenior Managing Director

In terms of just the payments themselves, my understanding is that this was on the basis of consensus estimates as they stand today. I mean, that would sort of speak to some degree validation of where the consensus is today, but also the opportunity to see upside. Can you just talk a little bit about how that structure reflects what was a part of the agreement?

David MeekerChairman, President, and CEO

Yeah, I think you summarized it well. Obviously, consensus numbers, as long as, quote unquote, "we felt comfortable with them," they were out there. I think for both parties, it was an easy way to align around how to assess value. Again, that was a good path forward. But implicit in that is, yeah, we had to feel good about those numbers, and I think obviously we did the deal, and we do. So, and then the potential, the upside here, my view of rare diseases, again, as many of you have heard me say many times, they tend not to inflect for a variety of reasons. You should not think about rare diseases as peak, zero to peak in five years kind of thing, and then you plateau. Rare diseases almost invariably tend to be opportunities that just grow for years.

David MeekerChairman, President, and CEO

I think there's many examples, some of which I was part of, where they grow for decades. Part of that is you continue to penetrate more deeply into your original epi, and not uncommonly, your original epi is light, and so more patients are found. For those of you who know the Genzyme story, back to Gaucher, I think Gaucher is a good indication or a good example of a disease where the epi was very modest out of the gate back in the early 1990s, and after decades of work, the numbers have continued to grow. Yeah, I think those are both things that drive value here.

Seamus FernandezSenior Managing Director

A lot of times we hear in biotech, "Don't touch debt," that kind of a thing. You guys definitely made a decision to pursue the debt facility here. Can you talk a little bit about that and how you're thinking about the sort of relative cost of equity versus what you can accomplish with this debt facility?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day